J Mult Scler Neuroimmunol.
2024 Jun;15(1):17-22. 10.59578/jmsni.2024.15.1.17.
Monoclonal Antibody Treatment for Relapse Prevention in Neuromyelitis Optica Spectrum Disorder
- Affiliations
-
- 1Department of Neurology, National Cancer Center, Goyang, Korea
- KMID: 2561998
- DOI: http://doi.org/10.59578/jmsni.2024.15.1.17
Abstract
- Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disease of the central nervous system that can lead to devastating neurological disabilities such as blindness and impaired mobility. Given that NMOSD can cause severe neurological deteriorations even with a single episode, exploring effective relapse prevention strategies in NMOSD is imperative. Recently, various biological monoclonal antibody therapies targeting diverse mechanisms have shown efficacy in preventing relapses in NMOSD, as evidenced by clinical trials. These monoclonal antibody therapies include complement inhibition (eculizumab and ravulizumab), B-cell depletion (rituximab and inebilizumab), and interleukin-6 receptor blockade (tocilizumab and satralizumab) mechanisms. Some of these therapies are now reimbursable, and this review summarizes their mechanisms, administration methods, reimbursement status in Korea, efficacy, and safety profiles in clinical practice.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Early relapse after rituximab treatment in a patient with seronegative neuromyelitis optica spectrum disorder: a case report
- Postpartum Relapse of Neuromyelitis Optica Spectrum Disorder after a Long Period of Spontaneous Remission
- Monoclonal Antibody Therapies for Neuromyelitis Optica Spectrum Disorder
- Monoclonal Antibody Therapies for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
- Central Hyperthemia Treated with Bromocriptine in a Patient with Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder
